|
|
Article: Introgen's ADVEXIN(R) Combined With Aventis' Taxotere(R) and Pharmacia's Adriamycin(R) in Development for Breast Cancer.
- Article from:
- PR Newswire
- Article date:
- January 13, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Progress of Phase 2 Clinical Trial Highlighted in Recent Article
A recent article in the Houston Chronicle highlights the early successes of Introgen's ADVEXIN(R) gene drug therapy in a phase 2 breast cancer study ongoing at The University of Texas M. D. Anderson Cancer Center. The article may be found at http://www.chron.com/content/chronicle/health/index.html . An archived version can be obtained at www.HoustonChronicle.com in the health and medicine section.
Assistant professor in M.D. Anderson's department of breast medical oncology, Dr. Massimo Cristofanilli, and the study's principal investigator said, "We've had promising results in the 12 ...